| Nov 14 |
Anebulo Pharmaceuticals GAAP EPS of -$0.08
|
| Nov 13 |
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
|
| Sep 26 |
Anebulo Pharmaceuticals GAAP EPS of -$0.05
|
| Sep 25 |
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
|
| Sep 22 |
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
|
| Jul 22 |
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
|
| Jul 1 |
Lifecore Biomedical Announces Cooperation Agreement with 22NW
|
